期刊
ANTIBODIES
卷 6, 期 4, 页码 -出版社
MDPI
DOI: 10.3390/antib6040016
关键词
TRAIL; death-receptor targeting; ligand; cancer therapy; apoptosis; antibody; bi-specific; antibody drug conjugate; chimeric antigen receptor; scFv
类别
资金
- ANR (Agence Nationale de la Recherche) program Investissements d'Avenir Labex LipSTIC [ANR-11-LABX-0021-01]
- ANR [07-PCV-0031]
- Conseil Regional de Bourgogne
- FEDER (Fonds Europeen de Developpement Regional) [BG0003196]
- INCa (Institut National du Cancer) [POLYNOM-174]
- Canceropole Grand-Est, la Ligue Nationale Contre le Cancer
- fondation ARC (Association pour la Recherche sur le cancer)
Developing therapeutics that induce apoptosis in cancer cells has become an increasingly attractive approach for the past 30 years. The discovery of tumor necrosis factor (TNF) superfamily members and more specifically TNF-related apoptosis-inducing ligand (TRAIL), the only cytokine of the family capable of eradicating selectively cancer cells, led to the development of numerous TRAIL derivatives targeting death receptor 4 (DR4) and death receptor 5 (DR5) for cancer therapy. With a few exceptions, preliminary attempts to use recombinant TRAIL, agonistic antibodies, or derivatives to target TRAIL agonist receptors in the clinic have been fairly disappointing. Nonetheless, a tremendous effort, worldwide, is being put into the development of novel strategic options to target TRAIL receptors. Antibodies and derivatives allow for the design of novel and efficient agonists. We summarize and discuss here the advantages and drawbacks of the soar of TRAIL therapeutics, from the first developments to the next generation of agonistic products, with a particular insight on new concepts.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据